Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications

References

• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–1203.
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Schizophrenia. 2020. [cited 2020 Mar]. Available from: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml
   Google Scholar
• Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2197–2223.
   PubMed Web of Science ®Google Scholar
• Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016;3(2):171–178.
   PubMed Web of Science ®Google Scholar
• Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013;346:f2539.
   PubMed Web of Science ®Google Scholar
• Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334–341.
   PubMed Web of Science ®Google Scholar
• Chong HY, Teoh SL, Wu DB, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373.
   PubMed Web of Science ®Google Scholar
• NICE CG178. Psychosis and schizophrenia in adults: prevention and management. 2014.[cited 2020 Mar]. Available from: https://www.nice.org.uk/guidance/cg178/resources/psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-35109758952133
   Google Scholar
• Hui CLM, Lam BST, Lee EHM, et al. A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia. Int Rev Psychiatry. 2019;31(5–6):441–459.
   PubMed Web of Science ®Google Scholar
• Armstrong KS, Temmingh H. Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: findings from a cross-sectional study in an upper-middle-income country. Rev Bras Psiquiatr. 2017;39(4):293–301.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Smith RC, Leucht S, Davis JM. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl). 2019;236(2):545–559.
   Web of Science ®Google Scholar
• Mahmood S, Hussain S, Ur Rehman T, et al. Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future. Curr Med Res Opin. 2019;35(1):51–61.
   PubMed Web of Science ®Google Scholar
• Ramadas S, Kuttichira P, Sumesh TP, et al. A study of an antipsychotic prescription pattern of patients with schizophrenia in a developing country. Indian J Psychol Med. 2010;32(1):13–16.
   PubMedGoogle Scholar
• Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1998;173:325–329.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17(7):1083–1093.
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1–3):91–100.
   PubMed Web of Science ®Google Scholar
• Dong M, Zeng LN, Zhang Q, et al. Antipsychotic polypharmacy in older adult Asian patients with schizophrenia: research on Asian psychotropic prescription pattern. J Geriatr Psychiatry Neurol. 2019;32(6):304–311.
   PubMed Web of Science ®Google Scholar
• Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;11:Cd006625.
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;1:Cd006626.
   Google Scholar
• Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;11:Cd006633.
   Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;3:Cd006654.
   Google Scholar
• Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13(2):137–177.
   PubMedGoogle Scholar
• Swartz MS, Stroup TS, McEvoy JP, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv (Washington, DC). 2008;59(5):500–506.
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007;68(2):e04.
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.
   PubMed Web of Science ®Google Scholar
• Chan HY, Pan YJ, Chen JJ, et al. Time to discontinuation of second-generation antipsychotics versus haloperidol and sulpiride in people with schizophrenia: a naturalistic, comparative study. J Clin Psychopharmacol. 2017;37(1):13–20.
   PubMed Web of Science ®Google Scholar
• Vanasse A, Blais L, Courteau J, et al. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand. 2016;134(5):374–384.
   PubMed Web of Science ®Google Scholar
• Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophr Res. 2014;152(1):246–254.
   PubMed Web of Science ®Google Scholar
• Zuppo IF, Ruas CM, de Oliveira HN, et al. Health equity and the usage of atypical antipsychotics within the Brazilian national health system: findings and implications. Expert review of pharmacoeconomics & outcomes research; 2020.
   Google Scholar
• Barbosa WB, Costa JO, de Lemos LLP, et al. Costs in the treatment of schizophrenia in adults receiving atypical antipsychotics: an 11-year cohort in Brazil. Appl Health Econ Health Policy. 2018;16(5):697–709.
   PubMed Web of Science ®Google Scholar
• Guerra-Junior AA, Pires de Lemos LL, Godman B, et al. Health technology performance assessment: real-world evidence for public healthcare sustainability. Int J Technol Assess Health Care. 2017;33(2):279–287.
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of health of Brazil. Secretary of science, technology and strategic inputs. Department of management and incorporation of health technologies. Methodological guidelines: health technology performance assessment. il. Brasília: Ministry of Health of Brazil; 2017. p. 45.
   Google Scholar
• Makady A, van Veelen A, Jonsson P, et al. Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies. PharmacoEconomics. 2018;36(3):359–368.
   PubMed Web of Science ®Google Scholar
• Eriksson I, Wettermark B, Persson M, et al. The early awareness and alert system in Sweden: history and current status. Front Pharmacol. 2017;8:674.
   PubMed Web of Science ®Google Scholar
• Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106(1):36–39.
   PubMed Web of Science ®Google Scholar
• Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163(2):185–194.
   PubMed Web of Science ®Google Scholar
• Guerra Junior AA, Pereira RG, Andrade EIG, et al. Building the national database of health centred on the individual: administrative and epidemiological record linkage - Brazil, 2000-2015. Int J Popul Data Sci. 2018;3(3):20.
   Google Scholar
• Cherchiglia ML, Guerra Júnior AA, Andrade EIG, et al. A construção da base de dados nacional em terapia renal substitutiva (TRS) centrada no indivíduo: aplicação do método de linkage determinístico-probabilístico. Rev Bras Estud Popul. 2007;24(1):163.
   Google Scholar
• WHO. WHO collaborating centre for drug statistics methodology. ATC/DDD Index. [cited 2020 Mar]. Available from: https://www.whocc.no/
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. Jama. 2003;290(12):1624–1632.
   PubMed Web of Science ®Google Scholar
• Lebowitz BD, Vitiello B, Norquist GS. Approaches to multisite clinical trials: the national institute of mental health perspective. Schizophr Bull. 2003;29(1):7–13.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56.
   PubMed Web of Science ®Google Scholar
• Godman B, Grobler C, Van-De-Lisle M, et al. Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opin Pharmacother. 2019;20(18):2237–2255.
   PubMed Web of Science ®Google Scholar
• Brasil. Ministério da Saúde. Lei nº 10.216, de 6 de abril de 2001. Dispõe sobre a proteção e os direitos das pessoas portadoras de transtornos mentais e redireciona o modelo assistencial em saúde mental. [cited 2020 Mar]. Available from: http://www.planalto.gov.br/ccivil_03/leis/leis_2001/l10216.htm
   Google Scholar
• Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. DAPE. Reforma psiquiátrica e política de saúde mental no Brasil. Brasília, novembro de 2005 [cited 2020 Mar]. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/Relatorio15_anos_Caracas.pdf
   Google Scholar
• Razzouk D. Accommodation and Health Costs of Deinstitutionalized People with Mental Illness Living in Residential Services in Brazil. Pharmacoecon Open. 2019;3(1):31–42.
   PubMed Web of Science ®Google Scholar
• Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090–2095.
   PubMed Web of Science ®Google Scholar
• Ndukwe HC, Nishtala PS. Time-to-First Discontinuation, Adherence and Persistence in New Users of Second-Generation Antipsychotics. JClin Psychopharmacol. 2016;36(6):649–657.
   Web of Science ®Google Scholar
• Brasil. Ministério da Saúde. Saúde de A Z. Saúde mental. 2020 [cited 2020 Mar]. Available from: https://saude.gov.br/saude-de-a-z/saude-mental
   Google Scholar
• Taipale H, Tanskanen A, Mehtälä J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68.
   PubMed Web of Science ®Google Scholar
• Noordsy DL, Glynn SM, Sugar CA, et al. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: eighteen-month outcomes. J Psychiatr Res. 2017;95:299–307.
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res. 2009;107(1):1–12.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–610.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis [published correction appears in Lancet. Lancet. 2019 Sep 14;394(10202):918.
   Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611–622.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: international Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.
   PubMed Web of Science ®Google Scholar
• Manu P, Lapitskaya Y, Shaikh A, et al. Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther. 2018;25(2):e218–e23.
   PubMed Web of Science ®Google Scholar
• Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Freudenreich O, Sayer MA, et al. Addressing barriers to clozapine underutilization: a national effort. Psychiatric Serv. 2018;69(2):224–227.
   PubMed Web of Science ®Google Scholar
• Parks J, Radke A, Parker G, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull. 2009;35(5):931–936.
   PubMed Web of Science ®Google Scholar
• Godman B, Petzold M, Bennett K, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med. 2014;12:98.
   PubMed Web of Science ®Google Scholar
• Maia Diniz I, Guerra AAJ, Lovato Pires de Lemos L, et al. The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. PloS One. 2018;13(6):e0199446.
   PubMed Web of Science ®Google Scholar
• Lemos LLP, Guerra Junior AA, Santos M, et al. The assessment for disinvestment of intramuscular interferon beta for relapsing-remitting multiple sclerosis in Brazil. PharmacoEconomics. 2018;36(2):161–173.
   PubMed Web of Science ®Google Scholar
• Gomes RM, Guerra Junior AA, Lemos LL, et al. Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Rev Clin Pharmacol. 2016;9(7):991–999.
   PubMed Web of Science ®Google Scholar
• Gomes RM, Barbosa WB, Godman B, et al. Effectiveness of maintenance immunosuppression therapies in a matched-pair analysis cohort of 16 years of renal transplant in the Brazilian national health system. Int J Environ Res Public Health. 2020;17:6.
   Web of Science ®Google Scholar
• Godoi IP, Da Silva LVD, Sarker AR, et al. Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine. Expert Rev Vaccines. 2018;17(12):1123–1133.
   PubMed Web of Science ®Google Scholar
• Dos Santos JBR, Guerra Junior AA, da Silva MRR, et al. First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Rev Clin Pharmacol. 2019;12(4):363–370.
   PubMed Web of Science ®Google Scholar